Compare Citius Pharmaceuticals Inc (CTXR) vs Nutrien Ltd (NTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Nutrien Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Nutrien Ltd trades at $68.65 (market cap $32.62B). The key difference: Nutrien Ltd is far larger — about 2228.1× Citius Pharmaceuticals Inc's market cap, and Nutrien Ltd pays a 3.21% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | NTR | |
|---|---|---|
Market Cap | $14.64M | $32.62B |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $83.94 |
52-Week Low | $0.53 | $53.64 |
Enterprise Value | $10.86M | $45.79B |
Dividend Yield | — | 3.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Nutrien (NTR) trades at $67.60, up 3.32% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 13.77 and net income margin of 8.58%. Recent earnings beat expectations in Q1 2026, and analyst consensus is strongly positive with a $79.50 price target. The company maintains solid cash flow from operations at $4.01 billion despite recent net cash outflows.
NTR presents a compelling value opportunity with reasonable valuation metrics and strong analyst support. Key risks include volatile fertilizer prices and global agricultural demand fluctuations. The upcoming Q2 2026 earnings report with expected EPS of $2.89 represents a significant near-term catalyst for price movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →
